• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biomea Fusion, Inc. - Common Stock (NQ:BMEA)

1.395 +0.005 (+0.36%)
Streaming Delayed Price Updated: 3:30 PM EDT, Jun 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biomea Fusion, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Biomea Fusion Inc (NASDAQ:BMEA) Q1 2026 Earnings Beat and Pipeline Progress Drive Cautious Optimism ↗
May 11, 2026
Via Chartmill
Topics Earnings
News headline image
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
May 11, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
May 05, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
April 27, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
March 31, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
March 24, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib ↗
March 14, 2026
Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data for icovamenib in type 2 diabetes, highlighting durable efficacy and a favorable safety profile. 
Via Benzinga
News headline image
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
March 14, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate at Upcoming Investor Conferences
February 19, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
January 12, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
December 09, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
December 05, 2025
Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 Diabetes 
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
December 02, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
December 01, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
December 01, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate at Upcoming Investor Conferences
November 24, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate at Jefferies London Healthcare Conference
November 10, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
November 05, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
November 04, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
October 30, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
October 27, 2025
Initial Clinical Data Expected in the First Half of 2026 
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
October 21, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Top stock movements in today's session. ↗
October 07, 2025
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
October 07, 2025
 
Via Benzinga
News headline image
Which stocks are moving on Tuesday? ↗
October 07, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study ↗
October 07, 2025
Biomea Fusion reported favorable safety for icovamenib in a 52-week diabetes study, alongside a $25 million public offering. 
Via Benzinga
News headline image
Tuesday's session: gap up and gap down stocks ↗
October 07, 2025
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Dow Jumps Over 100 Points; McCormick Earnings Top Views ↗
October 07, 2025
 
Via Benzinga
Topics Stocks
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
October 07, 2025
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap